Completed PHASE1 INTERVENTIONAL 2-arm NCT02502500

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

An Open-label Study in Healthy Subjects to Assess the Effect of Once-daily Multiple Dosing of AKB-6548 on the Pharmacokinetics of the CYP2C9 Substrate Celecoxib

Sponsor: Akebia Therapeutics

Conditions Healthy Volunteers

Interventions AKB-6548 Celecoxib

Updated 8 times since 2017 Last updated: Nov 10, 2018 Started: Jul 31, 2015 Primary completion: Jul 31, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02502500, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Akebia Therapeutics, it has been updated 8 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2018 — Jan 2021 [monthly]

Completed PHASE1
Oct 2018 — Dec 2018 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Oct 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akebia Therapeutics

Data source: Akebia Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.